(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of -0.59% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.5%.
Viatris's revenue in 2023 is $15,465,600,000.On average, 2 Wall Street analysts forecast VTRS's revenue for 2023 to be $18,600,958,838,550, with the lowest VTRS revenue forecast at $18,526,159,351,700, and the highest VTRS revenue forecast at $18,675,758,325,400. On average, 2 Wall Street analysts forecast VTRS's revenue for 2024 to be $18,469,708,832,795, with the lowest VTRS revenue forecast at $18,428,266,198,100, and the highest VTRS revenue forecast at $18,511,151,467,490.
In 2025, VTRS is forecast to generate $18,202,752,043,520 in revenue, with the lowest revenue forecast at $17,920,805,365,100 and the highest revenue forecast at $18,484,698,721,940.